Clinical trial
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of…
NCT00220389 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00220389 |
|---|---|
| Title | Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase |
| Official title | Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder(OAB): a Double-Blind Phase Followed by an Open-Label Extension Phase |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug |
| Interventions | SPM 907 |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 16, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: